Fig 1: (a) Relative expression levels of IL-22 mRNA in mice of different ages with or without viral infection. The data were collected on the third day post-infection. (b) Relative expression levels of IL-17 mRNA in mice of different ages with or without viral infection. The data were collected on the third day post-infection. (c) Tissue levels of IL-22 and IL-17 in mice of different ages with or without viral infection. The data were collected on the third day post-infection. (d) Survival rates of mice after intervention with PBS, IL-22AB, or IL-17 following infection. (e) Changes in body weight of mice after intervention with PBS, IL-22AB, or IL-17 following infection. (f) Changes in clinical scores of mice after intervention with PBS, IL-22AB, or IL-17 following infection. (g) Tissue viral titers in mice after intervention with PBS, IL-22AB, or IL-17 following infection. The data were collected on the third day post-infection. (h) Skeletal muscle tissue of mice: 1. Mice on day 7 after IL-17 intervention following infection. 2. Mice on day 7 after IL-22AB intervention following infection. 3. Mice on day 10 after IL-17 intervention following infection. 4. Mice on day 10 after IL-22AB intervention following infection. 5. Uninfected mice. 6. Mice with PBS intervention. (Differences in mortality, body weight, and subsequent paralysis sequelae of mice were evaluated by mean ± SE values. p-values were evaluated by log-rank test (survival rates), Wilcoxon test (clinical scores), and Mann–Whitney U test (relative change in ILC3s, IL-22, and IL-17). p-values < 0.05 were considered statistically significant. * indicates p < 0.05).